Quest Diagnostics Director Acquires 6 Shares via Dividend Reinvestment

Insider Transaction Analysis: Quest Diagnostics Inc (NYSE: DGX)

Executive Summary

On October 23, 2026, Quest Diagnostics Inc reported an insider transaction conducted by Director Wright L. Lassiter III. The transaction involved the acquisition of 6 shares of Common Stock on October 21, 2026, at a price of $235.959 per share, totaling approximately $1,415.75.

Transaction Details

• Reporting Owner: Lassiter Wright III
• Role: Director
• Security: Common Stock
• Transaction Code: L (Acquisition pursuant to a dividend reinvestment plan)
• Shares Acquired: 6
• Price Per Share: $235.959
• Total Consideration: $1,415.75
• Ownership Type: Direct
• Post-Transaction Beneficial Ownership: 10,329 shares

Context & Significance

• Nature of Transaction: Footnote 1 indicates that the shares were acquired under a broker-administered dividend reinvestment plan (DRIP), eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person elected to report the transaction early on Form 4.
• Market Impact: Low. This is an automatic, routine reinvestment transaction of nominal monetary size and does not reflect a discretionary open-market purchase or strategic shift in insider sentiment.